Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1636 1645
This examiner grants 50% of resolved cases
Pricila NMN Hauk Teodoro has 6 resolved cases in Art Unit 1617 and Tech Center 1600. Her allowance rate is 50.0%, indicating an even split between grants and abandonments. This rate provides a baseline for the small number of cases resolved so far. The 50.0% allowance rate suggests a balanced approach to examination in this early docket relative to the 6 resolved cases.
The interview lift is 0.0%, suggesting that interviews have not yet shown a statistical impact on outcomes in this limited dataset. The 50.0% allowance rate remains the primary metric for success. Practitioners should also note the median days to allowance of 890. This 0.0% lift indicates that the 6 resolved cases have followed a standard written path without additional benefit from verbal discussion.
The 890-day timeline represents the typical duration for reaching a grant in this docket. With only 6 resolved cases, these figures offer an initial look at the prosecution environment in Art Unit 1617. The 890 median days and the 50.0% allowance rate together define the current experience for applicants. Practitioners should monitor these metrics as the number of resolutions increases over time.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18694893 | STRAIN FOR PRODUCING HIGH CONCENTRATION L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING THE SAME | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18836272 | NOVEL LIVE MULTI-ANTIGENIC RECOMBINANT VACCINE AGAINST TUBERCULOSIS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18535116 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | Final Rejection | Pfizer Inc. |
| 19068745 | ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS | Non-Final OA | Boehringer Ingelheim Vetmedica GmbH |
| 18839920 | LIPID PRODUCTION CONTROL FACTOR FOR OLEAGINOUS YEAST | Non-Final OA | FUJI OIL HOLDINGS INC. |
| 18291999 | GENE SIGNATURE PREDICTING TERTIARY LYMPHOID STRUCTURES CONTAINING B CELLS | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. |
| 18262937 | SINGLE-DOMAIN ANTIBODY AGAINST CD16A AND USE THEREOF | Non-Final OA | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy